CENTRE FOR DRUG DESIGN & DISCOVERY (CD3)
The Centre for Drug Design and Discovery (CD3) is an investment fund and technology transfer platform aimed at promoting the discovery and development of innovative medicines for all kinds of diseases. CD3 achieves this goal by building further on the enormous pool of basic knowledge, innovation and technology of universities and spin-off companies. By providing the necessary expertise and financial resources, CD3 ensures that fundamental biomedical research carried out by universities and small... biotech companies is translated into more usable results and promising molecules for new medicines. These new, potential medicines can then be further developed by pharmaceutical companies or form the basis for new spin-off companies. With this work method and philosophy, CD3 bridges the gap between academic innovative research and the pharmaceutical industry.
CENTRE FOR DRUG DESIGN & DISCOVERY (CD3)
Industry:
Biopharma Biotechnology Health Care Medical
Address:
Leuven, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.cd3.eu
Status:
Active
Contact:
(321)632-6484
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving IPv6 Google Maps API
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Okairos
Okairos AG is a biopharmaceutical company focused on the discovery and development of genetic T-cell vaccines, including hepatitis C virus.
OxiProteomics
OxiProteomics is a technology-based start-up committed to promoting the healthy living and healthy aging of human population.
SensAbues AB
SensAbues has the ultimate technology for drug testing non invasive and non intrusive!.
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-01-04 | Rewind Therapeutics | Centre for Drug Design & Discovery (CD3) investment in Series A - Rewind Therapeutics | 15.2 M EUR |
Official Site Inspections
http://www.cd3.eu
- Host name: web-rewrites.icts.kuleuven.be
- IP address: 134.58.64.162
- Location: Leuven Belgium
- Latitude: 50.8758
- Longitude: 4.7027
- Timezone: Europe/Brussels
- Postal: 3000
More informations about "Centre for Drug Design & Discovery (CD3)"
Organisation | Centre for Drug Design and Discovery - cd3.be
CD3 is established within KU Leuven Research & Development (LRD), allowing the flexibility to collaborate or partner with internal (KU Leuven) and external research groups, as well as with …See details»
CD3
CD3 is an investment fund and drug discovery center focusing on the discovery of new drugs based on innovative science from our partners. We bridge the gap between innovative biomedical research emerging from academic institutes or …See details»
About CD3 | Centre for Drug Design and Discovery
The Centre for Drug Design and Discovery (CD3), based in Leuven (Belgium), is a drug discovery centre and investment fund created to drive the translation of innovative basic research to the …See details»
KU Leuven, Centre for Drug Design and Discovery (CD3)
Jan 1, 2006 The Centre for Drug Design and Discovery ("CD3") was established in 2006 by KU Leuven Research and Development (LRD) and the European Investment Fund (EIF). CD3 is …See details»
CD3 IV (Centre for Drug Design and Discovery) - Access to EU …
CD3 IV (Centre for Drug Design and Discovery) - Access to EU Finance en English. Available languages. Close menu. bg български; cs čeština ... Rules for taking cash in and out of the …See details»
Centre for Drug Design & Discovery (CD3) - Crunchbase
The Centre for Drug Design and Discovery (CD3) is an investment fund and technology transfer platform aimed at promoting the discovery and development of innovative medicines for all kinds of diseases. CD3 achieves this goal by …See details»
The Centre for Drug Design and Discovery raises 70.5 Million …
19.10.2023 - The Centre for Drug Design and Discovery (CD3), a pioneering organization specializing in translating innovative biomedical research into life-saving medicines, today …See details»
Six bispecific antibody companies you should know about
Nov 19, 2024 Consequently, Candid has also acquired these companies’ lead assets, CND106 and CND261, respectively. CND106 targets B-cell maturation antigen, while CND261 binds to …See details»
KU Leuven develops very potent antiviral against dengue
Oct 7, 2021 Researchers at the KU Leuven Rega Institute and CD3 have developed an ultrapotent inhibitor of the dengue virus, which causes the tropical disease known as dengue. …See details»
Our team | Centre for Drug Design and Discovery - CD3
Patrick Chaltin is the Managing Director of the Centre for Drug Design and Discovery (CD3) since its start-up in 2006. He is a qualified European Patent Attorney and was previously active as IP manager at the IP unit of KU Leuven …See details»
A conformational epitope expressed upon association of CD3
Nov 1, 1991 The recognition by this panel of anti-CD3 antibodies of CD3-gamma/epsilon and CD3-delta/epsilon complexes and not of CD3-epsilon alone was assessed by …See details»
Summary of a workshop on preclinical and translational safety ...
The key safety concerns with CD3 bispecifics are excessive release of cytokines, which may translate to potentially life-threating cytokine release syndrome (CRS), target organ toxicity …See details»
CD3 (immunology) - Wikipedia
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T …See details»
Deciphering the TCR/CD3 Complex: A Gateway to Immune Hallmarks
What is CD3 CD3, also known as Cluster of Differentiation 3, is a pivotal protein molecule situated on the cell membrane, serving as a vital marker within the immune system. Present on the cell …See details»
Cancer vaccines compensate for the insufficient induction of …
Treatment with CD3 bsAbs achieved its breakthrough in the clinic with blinatumomab (CD3xCD19), which demonstrated response rates up to 90% in relapsed or refractory acute …See details»
Genomic organization of the human and chicken CD3 cluster. A, …
A, Sketch representing the human CD3 cluster organization (8, 9, 12). Approximate sizes of the CD3 genes and the intervening sequences are given. Note that the sketch does not represent …See details»
Brilliant Violet 605™ anti-human CD3 Antibody - BioLegend
CD3ε is a 20 kD chain of the CD3/T-cell receptor (TCR) complex which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T-cell receptor (α/β or γ/δ) heterodimer. It is …See details»
Imfinzi-based regimen demonstrated statistically significant and ...
Mar 7, 2025 Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million people diagnosed each year. 1 In 2024, there were roughly 43,000 drug-treated …See details»
Portfolio | Centre for Drug Design and Discovery - CD3
Over the years, CD3 has collaborated with academic research groups and companies in more than 30 projects in order to develop potential new medicines for various disorders. Browse …See details»
News | Centre for Drug Design and Discovery - CD3
The Centre for Drug Design and Discovery (CD3) today announced the successful closure of CD3 IV, raising 70.5 million euros. This investment brings the total capital managed by CD3 to …See details»